As of 2026-03-26, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (25.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.17 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -911.8%.
The range of the Relative Valuation is (25.33) - (26.36) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.7x - 23.4x | 21.5x |
| Forward P/E multiples | 19.8x - 21.6x | 20.6x |
| Fair Price | (25.33) - (26.36) | (25.73) |
| Upside | -899.1% - -931.5% | -911.8% |
| Date | P/E |
| 2026-03-24 | -2.59 |
| 2026-03-23 | -2.64 |
| 2026-03-20 | -2.66 |
| 2026-03-19 | -2.76 |
| 2026-03-18 | -2.72 |
| 2026-03-17 | -2.80 |
| 2026-03-16 | -2.77 |
| 2026-03-13 | -2.80 |
| 2026-03-12 | -2.69 |
| 2026-03-11 | -2.82 |
| 2026-03-10 | -2.81 |
| 2026-03-09 | -2.87 |
| 2026-03-06 | -2.83 |
| 2026-03-05 | -2.90 |
| 2026-03-04 | -2.98 |
| 2026-03-03 | -2.90 |
| 2026-03-02 | -2.97 |
| 2026-02-27 | -3.00 |
| 2026-02-26 | -3.08 |
| 2026-02-25 | -3.08 |
| 2026-02-24 | -2.89 |
| 2026-02-23 | -2.79 |
| 2026-02-20 | -2.80 |
| 2026-02-19 | -3.04 |
| 2026-02-18 | -2.89 |
| 2026-02-17 | -2.83 |
| 2026-02-13 | -2.85 |
| 2026-02-12 | -2.93 |
| 2026-02-11 | -3.03 |
| 2026-02-10 | -3.15 |
| 2026-02-09 | -3.26 |
| 2026-02-06 | -3.26 |
| 2026-02-05 | -2.91 |
| 2026-02-04 | -3.19 |
| 2026-02-03 | -3.35 |
| 2026-02-02 | -3.42 |
| 2026-01-30 | -3.43 |
| 2026-01-29 | -3.53 |
| 2026-01-28 | -3.66 |
| 2026-01-27 | -3.76 |
| 2026-01-26 | -3.75 |
| 2026-01-23 | -3.87 |
| 2026-01-22 | -4.06 |
| 2026-01-21 | -3.77 |
| 2026-01-20 | -3.60 |
| 2026-01-16 | -3.82 |
| 2026-01-15 | -3.80 |
| 2026-01-14 | -3.97 |
| 2026-01-13 | -3.84 |
| 2026-01-12 | -3.93 |